Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ¼¶³×ÀÏ 0page
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 1
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 2
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 3
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 4
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 5
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 6
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 7
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 8
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 9
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 10
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 11
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 12
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 13
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 14
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 15
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 16
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 17
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 18
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 19
Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ - ½æ³×ÀÏ 20
¼­½Ä»çÀü ÀÚ¼¼È÷ º¸±â ÀǾàÇ°

ÀǾàÇ° µîÀÇ ¾ÈÀü¿¡ °üÇÑ ±ÔÄ¢ [½ÃÇà 2015.7.1] [ÃѸ®·É Á¦1089È£, 2014.8.21, ÀϺΰ³Á¤]¿¡ ÀÇÇÑ [¼­½Ä 20] ÀǾàÇ°[Á¦Á¶ÆǸÅ, ¼öÀÔ(Ç°¸ñÇã°¡ °»½Å ½Åû¼­, Ç°¸ñ½Å°í °»½Å ½Å°í¼­)] ¾ç½ÄÀÔ´Ï´Ù.

¿¬°ü Ãßõ¼­½Ä
YF-COR-3956 Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ
  • ºÐ·®
  • Á¶È¸
  • ÀÌ¿ëµî±Þ
  • Èıâ Æò°¡
¼­·Ð, Ç×üÀǾàÇ° ½ÃÀå±Ô¸ð ¹× Àü¸Á, Ç×üÀǾàÇ° Çã°¡ ¹× °³¹ß ÇöȲ, Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ(Ç×üÀÇ ±¸Á¶¿Í ±â´É, °³¹ß ±â¹Ý ±â¼ú, È¿´É/¾ÈÁ¤¼º Çâ»ó ±â¼ú), ±â¼ú Àû¿ë »ç·Ê, °á·Ð µîÀÇ ³»¿ëÀ¸·Î ±¸¼ºµÇ¾ú½À´Ï´Ù. * Ãâó : ½ÄÇ°ÀǾàÇ°¾ÈÀüó (http://www.mfds.go.kr)
¿øÇÏ´Â Æ÷¸ËÀ¸·Î ´Ù¿î¹ÞÀ» ¼ö ÀÖ¾î¿ä.
  • Adobe PDF (pdf)
¿ùÁ¤¾×À¸·Î ÀÌ¿ëÇϱâ

¿ù 9,900¿øÀ¸·Î ¸ðµç ¼­½ÄÀ» ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ¾î¿ä.

9,900¿ø
Chat GPT
ºÐÀ§±â
  • ¿¹Àǹٸ¥
  • Ä£±ÙÇÑ
  • »ç¹«ÀûÀÎ
  • ´ÜÈ£ÇÑ
¸ñÂ÷
    1Àå ¼­·Ð

    2Àå Ç×üÀǾàÇ° ½ÃÀå±Ô¸ð ¹× Àü¸Á
    1. ¼¼°è ½ÃÀå ±Ô¸ð ¹× Àü¸Á
    2. ±¹³» ½ÃÀå ±Ô¸ð ¹× Àü¸Á

    3Àå Ç×üÀǾàÇ° Çã°¡ ¹× °³¹ß ÇöȲ
    1. ±¹³» Çã°¡ ¹× ÀÓ»ó ÇöȲ
    2. ±¹¿Ü °³¹ß ÇöȲ

    4Àå Ç×üÀǾàÇ° °³¹ß ±â¼ú µ¿Çâ
    1. Ç×üÀÇ ±¸Á¶¿Í ±â´É
    2. °³¹ß ±â¹Ý ±â¼ú
    3. È¿´É/¾ÈÁ¤¼º Çâ»ó ±â¼ú(Antibody engineering)

    5Àå ±â¼ú Àû¿ë »ç·Ê
    1. Muromonab-CD3(Orthoclone OKT3, Janssen)
    2. Infliximab(Remicade, Johnson & Johnson)
    3. Trastuzumab(Herceptin, Roche)
    4. Adalimumab(Humira, AbbVie)
    5. Brentuximab-vedotin(Adcetris, Seattle Genetics)

    6Àå °á·Ð

    7Àå Âü°í¹®Çå

ÀÌ¿ëÈıâ (0)

¼ÖÁ÷ÇÑ Èı⸦ ³²°ÜÁֽŠȸ¿ø´Ô²² ½ºÅ¸¹÷½º ±âÇÁƼÄÜÀ» µå¸³´Ï´Ù.

Èıâ ÀÛ¼º